Immunic, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 93.61 million compared to USD 120.41 million a year ago. Basic loss per share from continuing operations was USD 2.11 compared to USD 3.78 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.26 USD | +2.44% | +1.61% | -16.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.00% | 111M | |
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |
- Stock Market
- Equities
- IMUX Stock
- News Immunic, Inc.
- Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023